MO01.02 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States

Autor:	N. Varol, M. Berling, A. Lee, J. Klint, Yong Yuan, Mohammad A Chaudhary, Solomon Lubinga, E. Testa, P. Dale, John R. Penrod
Rok vydání:	2021
Předmět:	Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty business.industry Ipilimumab Cost-effectiveness analysis medicine.disease First line treatment Internal medicine medicine Non small cell Nivolumab Lung cancer business medicine.drug
Zdroj:	Journal of Thoracic Oncology. 16:S15-S16
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2020.10.050
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8d50bd1000503eba14a653a48c507d63 https://doi.org/10.1016/j.jtho.2020.10.050 Zobrazit plný text záznamu